TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06769217

Intervention type: DEVICE
Group type: OTHER
Intervention: Drug Eluting Coronary Stent
Description: The Drug Eluting Coronary stent is indicated for the treatment of de novo coronary artery lesions in patients with symptomatic ischemic heart disease.
Study: NCT06767475

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Attend a focus group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: Participate in group discussion with exercises and activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: Participate in group discussion with exercises and activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: Participate in group discussion with exercises and activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Attend a one-on-one interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06764953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-GRAFT ™
Description: E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FIBRACOL™
Description: 510K FDA cleared Collagen alginate dressing
Study: NCT06768645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetic foot care education delivered using the Pecha Kucha method
Description: The study commenced after obtaining ethical approval and written consent from the relevant institution. The Pecha Kucha presentation was prepared by the researcher, adhering to established literature and the specific requirements of the technique. The education covered six key topics: 1) Diabetes and Foot Problems, 2) Daily Foot Care, 3) Appropriate Socks, 4) Appropriate Footwear, 5) Nail Care, and 6) Daily Life Precautions. Expert opinions were sought from four academics (S.Ö; K.L; Z.Z; G.F) with expertise in the field to establish content validity for the final version of the Pecha Kucha diabetic foot care presentation. Following expert approval, a pilot study was conducted with 10 diabetic patients who met the sample group criteria. Feedback from these patients regarding system functionality, clarity, and flow was incorporated to finalize the presentation. Afterward, the finalized Pecha Kucha Information training was delivered to the experimental group. The presentations were cond

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional diabetic foot care education
Description: traditional diabetic foot care education
Study: NCT06767657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEA (carotid endarterectomy)
Description: Intervention (CEA) is associated to both arms (group A and B)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CEA (carotid endarterectomy)
Description: Intervention (CEA) is associated to both arms (group A and B)
Study: NCT06769022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting and Exercise Intensity Intervention
Description: Participants' goal-setting and exercise intensity are manipulated based on group assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting and Exercise Intensity Intervention
Description: Participants' goal-setting and exercise intensity are manipulated based on group assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting and Exercise Intensity Intervention
Description: Participants' goal-setting and exercise intensity are manipulated based on group assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting and Exercise Intensity Intervention
Description: Participants' goal-setting and exercise intensity are manipulated based on group assignment.
Study: NCT06766682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Skill Development Program for Emotion Regulation
Description: The Skill Development Program for Emotion Regulation to be carried out with the intervention group was planned as 6 sessions. The aim of this study was to investigate The Skill Development Program for Emotion Regulation Program on oncology nurses' emotion regulation difficulties, emotion regulation skills, experiential avoidance, and compassion fatigue.
Study: NCT06764901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Therapy Chat Service (TCS)
Description: Online Therapy Chat Service (TCS) based on CBT techniques from the Berlin Dissexuality Therapy (Beier, K. M. (2021). Pedophilia, hebephilia and sexual offending against children. The Berlin Dissexuality Therapy (BEDIT). Springer).
Study: NCT06765746

Intervention type: PROCEDURE
Intervention: Ventricular tachycardia ablation
Description: All ventricular tachycardia (VT) ablation procedures will be performed under general anesthesia. An epicardial approach will be performed, if clinically needed, when a detailed endocardial mapping during VT fails to reveal the complete VT critical isthmus. In case of epicardial mapping, the pericardium will be accessed percutaneously using the method described by Sosa et al.~VT activation mapping will be performed and the critical isthmus will be defined as the diastolic pathway.~Ablation will be performed at 50 W (temperature limit of 43 °C) using an irrigated ablation catheter (TactiFlex, Abbott, MN). Ablation will be aimed at VT isthmus transection. Substrate modification will be added if the patient is still inducible or in the absence of any inducible/tolerated VT. Substrate ablation will be performed based on sinus rhythm mapping, aiming at non-inducibility of any VT. At the end of procedure, programmed ventricular stimulation will be repeated.
Study: NCT06766110

Intervention type: OTHER
Intervention: Assessment
Description: 31 volunteer participants who were followed up at the Department of Chest Diseases, Istanbul University, Istanbul Faculty of Medicine and met the inclusion criteria were included in the study. Participants' body composition, upper extremity functional exercise capacity, grip strength, and activities of daily living were evaluated.
Study: NCT06768255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
Description: Abiraterone Acetate（II）

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate 1000 mg + prednisolone (5mg bid) +ADT
Description: Abiraterone acetate 1000 mg
Study: NCT06766006

Intervention type: PROCEDURE
Intervention: Venoarterial extracorporeal life support (VA ECLS) implant
Description: Implantation of venoarterial extracorporeal life support implant for refractory cardiogenic shock or cardiac arrest of any cause.
Study: NCT06767215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Compress
Description: Ice compress will be applied 5 minutes before butulinium injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No ice compress
Description: No ice compress will be applied .
Study: NCT06765993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide oral solution
Description: 30 mL, TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mL, TID
Study: NCT06766747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting
Description: Participants in the alternate-day fasting group will receive biweekly telecounseling to ensure adherence to the prescribed dietary plan and to monitor for potential adverse events. During the 12-week weight loss phase, patients are instructed to restrict calories to 75% of usual intake 2 days per week. A daily intake of at least 2 liters of low-energy beverages (water, caffeine- and sugar-free beverages) is generally recommended on fasting days. Usual physical activity is encourage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Continuous calorie restriction
Description: Participants in the continuous calorie restriction group will receive biweekly nutritional counseling via Telecoaching to ensure adherence to the prescribed dietary plan. Based on weekly caloric intake obtained from the 7-day log, a model menu will be prescribed with a 25% daily calorie restriction divided among 3 meals every day consisting of macronutrient intake, with 20% of energy as fat, 40 to 50% as carbohydrate, and 20 to 30% as protein. They will be instructed to continue their usual physical activity.
Study: NCT06766877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercise
Description: 1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: foot-ankle strengthening exercise
Description: 1. Isometric quadriceps exercises involving knee extension~2. Maximum isometric exercise for the quadriceps
Study: NCT06766266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome II combination therapy regimen
Description: In the A arm, the combined treatment with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the neoadjuvant therapy phase before TURBT surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome II combination therapy regimen
Description: In the B arm, the combined therapy with irinotecan liposome (intravenous injection, once every two weeks for 1 month, dose increasing regimen: 37.6 mg/m2 and 56.5mg/m2 ) and epirubicin (intravesical instillation, once a week for 1 month, 50 mg) is in the induction phase after TURBT surgery.
Study: NCT06765369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: The MD is characterized by increased consumption of legumes, whole grains, vegetables, fruits, nuts, seeds and olive oil, moderate consumption of fish, poultry and dairy foods, with low consumption of processed foods and red meat. The nutritional profile of the MD intervention will consist of 46% carbohydrates, 17% protein, and 35% fat. A significant focus on dietary fat consumption with maintaining an omega 6:3 ratio of approximately 3:1 or lower. The MD will provide fibre-rich foods to meet the fibre recommendations for Canadians (males: 30 grams/day, females: 21 grams/day)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Westernized Diet
Description: The WD is characterized by increased consumption of highly processed foods, refined grains, red meats, processed meats, added sugars, added salt, high intake of omega-6 PUFA, accompanied by a reduction in fibre, fruits and vegetables, whole grains, fish, as well as nuts and seeds.The nutrition composition of the WD intervention will consist of 46% of calories derived from refined carbohydrates and added sugars, 17% protein (sourced from red and processed meats) and 35% fat. The fatty acid profile will be characterized by higher amounts of n-6 PUFAs while lacking in n-3 PUFAs and MUFAs, with a omega 6:3 ratio of 15-20:1.
Study: NCT06765967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: displaying virtual reality images
Description: Patients were shown content filmed in 4K resolution through the glasses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music playback
Description: With the permission of the Turkish Music Research and Promotion Group (TÜMATA), 'Acemaşiran Makamı' was played.
Study: NCT06765239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hayfever Care
Description: Powdered natural food supplement provided as a decoction, to be taken twice daily.~Personalized Diet and Nutrition Guidance along with Lifestyle Advice

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list Control
Description: Personalized Diet and Lifestyle Advice
Study: NCT06765187

Intervention type: BIOLOGICAL
Intervention: RIV3
Description: intramuscular injection
Study: NCT06768684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief behavioral counseling
Description: Participants receive a two-session phone-based alcohol risk reduction intervention based on principles of harm reduction. Participants receive personalized feedback regarding how alcohol use may impact their health. Following a motivational enhancement exercise, participants are advised to reduce alcohol intake to within recommended limits. Evidence-based strategies are discussed (e.g., goal setting, self-monitoring, identifying and avoiding triggers, dealing with urges, pacing and spacing drinks, managing high risk situations, finding alternatives to alcohol, developing refusal skills, and enlisting social support). Educational materials addressing methods for cutting down are also provided, along with information about other available resources to support their efforts.
Study: NCT06769516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation (aVNS)
Description: This intervention involves transcutaneous auricular vagus nerve stimulation (taVNS) using the VagusStim device. The device consists of earphones tailored to fit the individual's ear size (S, M, L) and is connected to a TENS unit. The stimulation is applied to the tragus and concha of the ear for 30 minutes, three times a week, over a 4-week period. The device operates with a pulse duration of less than 500 microseconds, a frequency of 10 Hz, and in a modulated TENS mode. The current intensity is individually adjusted to the participant's sensory threshold. This method targets the vagus nerve to potentially regulate autonomic activity and improve symptoms of Irritable Bowel Syndrome (IBS).~The study combines this intervention with a low FODMAP diet for all participants, distinguishing it from studies focused solely on vagus nerve stimulation or dietary changes.
Study: NCT05352672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study: NCT06769516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Therapy
Description: This intervention involves a structured aerobic exercise program designed to improve physical activity levels and modulate symptoms of Irritable Bowel Syndrome (IBS). Participants engage in walking exercises at a moderate intensity, maintaining 50-70% of their maximum heart rate, ensuring the ability to converse comfortably during the activity. The exercise sessions last for at least 30 minutes, three days a week, on alternate days, over a 4-week period.~Participants are individually trained and monitored to ensure proper technique and adherence to the exercise protocol. The intervention is combined with a low FODMAP diet, providing a multimodal approach to IBS symptom management. This distinguishes it from other interventions by emphasizing physical activity's role in enhancing gastrointestinal and overall health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet Intervention
Description: This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications.
Study: NCT05236374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beef protein
Description: Animal protein source

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef protein
Description: Animal protein source
Study: NCT05996341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: 12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: 12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood flow restriction
Description: 12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
Study: NCT05830734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of freshly collected adipose cells
Description: A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bascoms Cleft lift procedure
Description: The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bascoms Cleft lift procedure
Description: The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
Study: NCT05830136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate Ringer's solution
Description: Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate Ringer's solution
Description: Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
Study: NCT04796506

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Resistance Training (PRT)
Description: PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by \>24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training (PRT)
Description: PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by \>24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Exercise Training (DE)
Description: PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.